Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Giardia intestinalis | Putative fructose-1,6-bisphosphate aldolase | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Candida albicans | fructose-bisphosphate aldolase | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 358 aa | 22.6 % |
Mycobacterium tuberculosis | Probable fructose-bisphosphate aldolase Fba | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 361 aa | 25.5 % |
Candida albicans | fructose-bisphosphate aldolase | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 358 aa | 22.6 % |
Mycobacterium ulcerans | fructose-bisphosphate aldolase | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 361 aa | 26.9 % |
Mycobacterium leprae | Probable fructose bisphosphate aldolase Fba | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 361 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | jun protein | 0.0248 | 0.6918 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.0186 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0019 | 0.0186 | 0.5 |
Echinococcus granulosus | jun protein | 0.0248 | 0.6918 | 1 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0248 | 0.6918 | 1 |
Entamoeba histolytica | fructose-1,6-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0182 | 0.4997 | 0.7223 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0019 | 0.0186 | 0.0278 |
Giardia lamblia | Fructose-bisphosphate aldolase | 0.0353 | 1 | 1 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0019 | 0.0186 | 0.027 |
Loa Loa (eye worm) | hypothetical protein | 0.0182 | 0.4997 | 0.7437 |
Mycobacterium leprae | Probable fructose bisphosphate aldolase Fba | 0.0172 | 0.4702 | 0.5 |
Onchocerca volvulus | 0.0195 | 0.5356 | 1 | |
Treponema pallidum | fructose-bisphosphate aldolase | 0.0353 | 1 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0019 | 0.0186 | 0.0336 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0019 | 0.0186 | 0.027 |
Onchocerca volvulus | 0.0182 | 0.4997 | 0.933 | |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0201 | 0.5555 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0019 | 0.0186 | 0.0336 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.0186 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Schistosoma mansoni | jun-related protein | 0.0201 | 0.5555 | 1 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Toxoplasma gondii | exonuclease III APE | 0.0019 | 0.0186 | 0.5 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0019 | 0.0186 | 0.027 |
Brugia malayi | hypothetical protein | 0.0195 | 0.5356 | 0.7741 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.0186 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0019 | 0.0186 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0019 | 0.0186 | 0.5 |
Brugia malayi | bZIP transcription factor family protein | 0.0248 | 0.6918 | 1 |
Mycobacterium ulcerans | fructose-bisphosphate aldolase | 0.0172 | 0.4702 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0248 | 0.6918 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0241 | 0.6719 | 1 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.0186 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Mycobacterium tuberculosis | Probable fructose-bisphosphate aldolase Fba | 0.0172 | 0.4702 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 6.2946 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia. (Class of assay: confirmatory) [Related pubchem assays: 2472, 2464 ] | ChEMBL. | No reference |
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Vif-A3F Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | 35.4813 uM | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 84.9214 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.